Background: Current venous thromboembolism guidelines recommend using direct oral
anticoagulants (DOACs) over warfarin regardless of obesity status; however, evidence …

Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a
decreased risk of bleeding when compared to warfarin for the treatment of venous …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Abstract Background Direct oral anticoagulants (DOACs) are the preferred treatment for
venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 …

PURPOSE: There is a paucity of clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy and …

Background: While commonly prescribed today, direct oral anticoagulants (DOACs) have
historically been avoided in patients with class III obesity or a weight> 120 kg due to limited …

Current literature on the safety and efficacy of direct oral anticoagulants (DOACs) in patients
of extreme weights are limited, however, they are still being prescribed in these populations …

Background: Consensus statements have recommended against the use of direct oral
anticoagulants (DOACs) in venous thromboembolism (VTE) for patients≥ 120 kg and≥ 40 …

Background: Direct-acting oral anticoagulants (DOACs) have become the preferred drugs
for managing venous thromboembolism (VTE). Despite their advantages over vitamin K …